16 September 2026 editorial review · Item
AT278 (U500 ultra-rapid insulin aspart): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: AT278 (U500 ultra-rapid insulin aspart)
Scope and findings:
- AddedmissedonlineJuly30T2pharmacologypaper,notOctoberfuturedata;scopekeptdistinctfromT1DandAID. CurrentportfoliopreparatorySequelphase2workverified.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.